Immunology | Preclinical Developments | UNITED STATES

Artax Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158

Lead Product(s): AX-158

Therapeutic Area: Immunology Product Name: AX-158

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

Artax Biopharma is poised to enter clinical trials with the small molecule AX- 158, a novel approach to treat multiple autoimmune diseases without causing the immunosuppression commonly associated with current autoimmune disease therapies.

Melior Discovery

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19

Lead Product(s): SFA005

Therapeutic Area: Immunology Product Name: SFA005

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: SFA Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 24, 2020

Details:

In this important effort to counter the effects of the COVID-19 virus SFA005 is expected to address the cytokine storm linked to Acute Respiratory Distress Syndrome (ARDS) experienced by patients infected with COVID-19.

TFF Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powder

Lead Product(s): Tacrolimus

Therapeutic Area: Immunology Product Name: TFF TAC-LAC

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 18, 2020

Details:

The Company intends to begin Single Ascending Dose Phase I studies in Tacrolimus Inhalation Powder later this month in Australia, with Multiple Ascending Dose studies.

Artax Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy

Lead Product(s): AX-158

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Columbus Venture Partners

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Series B Financing June 04, 2020

Details:

Proceeds from the financing will be used to support activities for a planned Q4 2020 filing of a Clinical Trial Application (CTA) with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for AX-158.

Alpine Immune Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases

Lead Product(s): ALPN-30x

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

First presentation of Alpine’s Variant Tumor Necrosis Factor (TNF) Receptor Domain (vTD) Program demonstrating expanded applicability of its directed evolution platform.

Theraly Fibrosis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Theraly Fibrosis Granted US Orphan Drug Designation for TLY012 for Systemic Sclerosis

Lead Product(s): TLY012

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

TLY012 is shown to reverse skin fibrosis in preclinical models of scleroderma.

Rallybio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Rallybio Further Broadens Drug Development Capabilities with Addition of Róisín Armstrong, PhD

Lead Product(s): RLYB211

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

Róisín Armstrong, PhD. Dr. Armstrong, a seasoned drug developer, will head the development of the Company’s lead program, RLYB211. RLYB211, a plasma-derived hyperimmune globulin, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Rallybio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Rallybio Scores $145M, Unveils Lead Rare Disease Program

Lead Product(s): RLYB211

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Pivotal bioVenture Partners

Deal Size: $145.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 19, 2020

Details:

Proceeds from the financing will be used to advance Rallybio’s current portfolio of product candidates targeting devastating rare diseases, including its lead program, RLYB211. RLYB211 is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia.

CytoAgents

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm

Lead Product(s): GP1681

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $1.6 million Upfront Cash: Undisclosed

Deal Type: Funding May 13, 2020

Details:

The Phase II SBIR grant is non-dilutive funding from the National Institute of Allergy and Infectious Diseases of the NIH and will advance the research of GP1681.

Singota Solutions

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Singota Solutions Collaborates with Noveome Biotherapeutics

Lead Product(s): ST266

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Noveome Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 12, 2020

Details:

Under the terms of the collaboration, Singota will manufacture Noveome’s ST266 to be used for IV infusion in Phase I and II clinical trials.

Find

Find Novel Immunology Drugs in Preclinical Development in UNITED STATES

United States

Product Type

Companies

Artax Biopharma

Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158

Melior Discovery

Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19

TFF Pharmaceuticals

TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powder

Artax Biopharma

Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy

Alpine Immune Sciences

Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases

Theraly Fibrosis

Theraly Fibrosis Granted US Orphan Drug Designation for TLY012 for Systemic Sclerosis

Rallybio

Rallybio Further Broadens Drug Development Capabilities with Addition of Róisín Armstrong, PhD

Rallybio

Rallybio Scores $145M, Unveils Lead Rare Disease Program

CytoAgents

CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm

Singota Solutions

Singota Solutions Collaborates with Noveome Biotherapeutics